Note: Ingredients listed on restricted chemical lists
EC/CAS
57-50-1
Name of the chemical
Sucrose, pure C12H22O11
Concentration
N/A
EC/CAS
99-76-3
Name of the chemical
4-hydroxybenzoic acid, methyl ester
Concentration
N/A
EC/CAS
1310-73-2
Name of the chemical
sodium hydroxide
Concentration
N/A
EC/CAS
25956-17-6
Name of the chemical
Disodium 6-hydroxy-5-[(2-methoxy-4-sulphonato-m-tolyl)azo]naphthalene-2-sulphonate (17); (CI 16035)
Concentration
N/A
EC/CAS
77-92-9
Name of the chemical
Citric acid
Concentration
N/A
General Information
Version
04
Revision date
2024-11-26
Product name
Valproic Acid Oral Solution, USP
1.2.1 Relevant identified uses
Pharmaceutical product used as an anti-epileptic drug
Emergency telephone
800.424.9300
Icons in SDS
Company Information
company name
Pharmaceutical Associates, Inc
Section 2
SECTION 2: Hazards identification
OSHA Hazards Classification This product is a mixture and is a pharmaceutical product. It is considered non-
Precautionary statements
General advice: Seek medical attention in case of accidental exposure or overdose. Eyes: Avoid contact with eyes. Skin Contact: Avoid skin contact. Inhalation: Not intended for inhalation. Ingestion: Generally safe at recommended doses. In case of overdose, seek medical attention immediately.
Storage
There are no special storage conditions for safety. For product integrity, store under conditions specified on the label.
Disposal
Dispose of in accordance with applicable laws and regulations.
2.1 Classification of the substance or mixture
This product is a mixture and is a pharmaceutical product. It is considered non- Hazardous according to the OSHA Hazard Communication Standard 2012 (29 CFR 1910.1200). Chemical family: Mixture Statement of Hazard: May be harmful if swallowed. May cause skin irritation, serious eye irritation May damage the unborn child. May cause nervous system and reproductive effects Additional Hazard Information: Short term: May damage fertility or the unborn child. Hepatotoxicity, including fatalities, usually during the first 6 months of treatment have been reported. Children with a mitochondrial disorder are at particular risk. Fetal risk, particularly neural tube defects, other malformations and decreased IQ have reported for infants born to mothers who took Valproic Acid during pregnancy. Cases of pancreatitis, including fatal hemorrhagic cases have also been reported. Long term: No additional information available EU Indication of danger: Not classified. 04 Emergency overview Seek medical attention in case of accidental exposure or overdose. The product is generally safe when used as prescribed. Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential of exposure in your workplace.
